{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:32:18Z","timestamp":1767598338104,"version":"3.41.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.phrs.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T15:16:37Z","timestamp":1484493397000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?"],"prefix":"10.1016","volume":"119","author":[{"given":"Maria Antonella","family":"Burza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Napoleone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.phrs.2017.01.015_bib0010","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3748\/wjg.v20.i10.2555","article-title":"Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis","volume":"20","author":"Bolognesi","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.phrs.2017.01.015_bib0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.dld.2005.02.009","article-title":"Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients","volume":"37","author":"Thalheimer","year":"2005","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/hep.23710","article-title":"Hepatic venous pressure gradient in 2010: optimal measurement is key","volume":"51","author":"Burroughs","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1590\/S1807-59322011000100021","article-title":"Prediction of large esophageal varices in cirrhotic patients using classification and regression tree analysis","volume":"66","author":"Hong","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"issue":"9","key":"10.1016\/j.phrs.2017.01.015_bib0035","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","article-title":"Practice Guidelines Committee of the American Association for the Study of Liver Diseases Practice Parameters Committee of the American College of, prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"102","author":"Garcia-Tsao","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00420-8","article-title":"Incidence and natural history of small esophageal varices in cirrhotic patients","volume":"38","author":"Merli","year":"2003","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.phrs.2017.01.015_bib0045","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198810133191505","article-title":"Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study","volume":"319","author":"North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0050","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-1007133","article-title":"Pharmacological treatment of portal hypertension: an evidence-based approach","volume":"19","author":"D'Amico","year":"1999","journal-title":"Semin. Liver Dis."},{"issue":"9","key":"10.1016\/j.phrs.2017.01.015_bib0055","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3748\/wjg.v20.i9.2127","article-title":"Gender specific medicine in liver diseases: a point of view","volume":"20","author":"Durazzo","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2007.08.013","article-title":"Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis","volume":"48","author":"Al-Chalabi","year":"2008","journal-title":"J. Hepatol."},{"issue":"23","key":"10.1016\/j.phrs.2017.01.015_bib0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study","volume":"305","author":"Lebrec","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0070","first-page":"75","article-title":"Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding","volume":"9","author":"Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients","year":"1989","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2017.01.015_bib0075","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.1840130517","article-title":"Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial The Boston-New Haven-Barcelona Portal Hypertension Study Group","volume":"13","author":"Conn","year":"1991","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJM198601233140412","article-title":"A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension","volume":"314","author":"Pagliaro","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2017.01.015_bib0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2165\/00003495-198900372-00010","article-title":"A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding","volume":"37","author":"Pagliaro","year":"1989","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000166165","article-title":"Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats","volume":"42","author":"Alatsakis","year":"2009","journal-title":"Eur. Surg. Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0168-8278(91)90817-U","article-title":"Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats","volume":"13","author":"Lin","year":"1991","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0105","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1172\/JCI115062","article-title":"Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension","volume":"87","author":"Sarin","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0110","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1053\/gast.1997.v112.pm9178694","article-title":"The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices","volume":"112","author":"Escorsell","year":"1997","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.phrs.2017.01.015_bib0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00042737-199907000-00011","article-title":"Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-speaking club for the study of portal hypertension","volume":"11","author":"Cal\u00e9s","year":"1999","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2004.05.004","article-title":"A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis","volume":"127","author":"Merkel","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12072-012-9353-8","article-title":"Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial","volume":"7","author":"Sarin","year":"2013","journal-title":"Hepatol. Int."},{"issue":"10","key":"10.1016\/j.phrs.2017.01.015_bib0130","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3748\/wjg.v21.i10.3100","article-title":"Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis","volume":"21","author":"Qi","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"21","key":"10.1016\/j.phrs.2017.01.015_bib0135","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0140","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1067\/mge.2000.105983","article-title":"Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial","volume":"51","author":"Avgerinos","year":"2000","journal-title":"Gastrointest. Endosc."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/jhep.2003.50032","article-title":"Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study","volume":"37","author":"Abecasis","year":"2003","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2017.01.015_bib0150","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/0016-5085(93)90158-9","article-title":"Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial","volume":"105","author":"Ter\u00e9s","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0155","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/hep.22358","article-title":"Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding","volume":"48","author":"Lo","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.phrs.2017.01.015_bib0160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1572-0241.2004.40246.x","article-title":"The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension","volume":"99","author":"Merli","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.phrs.2017.01.015_bib0170","first-page":"CD004544","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9361","key":"10.1016\/j.phrs.2017.01.015_bib0175","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(03)12778-X","article-title":"Prevention of variceal rebleeding","volume":"361","author":"Bosch","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0180","first-page":"289","article-title":"Report of the Baveno VI consensus workshop","volume":"15","author":"Cardenas","year":"2016","journal-title":"Ann. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2017.01.015_bib0185","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/gut.2008.171207","article-title":"Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial","volume":"58","author":"Garc\u00eda-Pag\u00e1n","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/jhep.2000.16236","article-title":"Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial","volume":"32","author":"Lo","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0195","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0200","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/gast.2002.35351","article-title":"Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding","volume":"123","author":"Lo","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0205","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1053\/gast.2002.35955","article-title":"A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis","volume":"123","author":"Patch","year":"2002","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.phrs.2017.01.015_bib0210","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s10620-005-2877-1","article-title":"Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate\/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients","volume":"50","author":"Sarin","year":"2005","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2036.2006.03007.x","article-title":"Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial","volume":"24","author":"Romero","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2017.01.015_bib0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/liv.12360","article-title":"Beta-blockers in portal hypertension: new developments and controversies","volume":"34","author":"Tripathi","year":"2014","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis","volume":"30","author":"Ba\u00f1ares","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2017.01.015_bib0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-8278(87)80012-0","article-title":"Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis","volume":"4","author":"Mastai","year":"1987","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/1319-3767.77251","article-title":"Carvedilol in the treatment of portal hypertension","volume":"17","author":"Al-Ghamdi","year":"2011","journal-title":"Saudi J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.amjhyper.2005.11.011","article-title":"Carvedilol action is dependent on endogenous production of nitric oxide","volume":"19","author":"Afonso","year":"2006","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0245","doi-asserted-by":"crossref","first-page":"e0148868","DOI":"10.1371\/journal.pone.0148868","article-title":"Carvedilol Improves Inflammatory Response, Oxidative Stress and Fibrosis in the Alcohol-Induced Liver Injury in Rats by Regulating Kuppfer Cells and Hepatic Stellate Cells","volume":"11","author":"Ara\u00fajo J\u00fanior","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0255","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis","volume":"36","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0260","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1440-1746.2002.02674.x","article-title":"Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics","volume":"17","author":"De","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.phrs.2017.01.015_bib0265","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/j.1572-0241.2004.40179.x","article-title":"Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis","volume":"99","author":"Lin","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0270","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.dld.2013.10.013","article-title":"Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study","volume":"46","author":"Hobolth","year":"2014","journal-title":"Dig. Liver Dis."},{"issue":"11","key":"10.1016\/j.phrs.2017.01.015_bib0275","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0280","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2013.11.019","article-title":"Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial","volume":"60","author":"Shah","year":"2014","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2017.01.015_bib0285","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2012.07244.x","article-title":"Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding","volume":"27","author":"Lo","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2017.01.015_bib0290","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2014.06.015","article-title":"Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding","volume":"61","author":"Stanley","year":"2014","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0295","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.phrs.2017.01.015_bib0300","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0305","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","article-title":"Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study","volume":"55","author":"Serst\u00e9","year":"2011","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0310","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2015.12.012","article-title":"Beta blockers in cirrhosis: The window re-opens","volume":"64","author":"Garcia-Tsao","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0315","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2014.03.040","article-title":"An apology for beta blockers","volume":"61","author":"Thalheimer","year":"2014","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0320","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1053\/j.gastro.2007.10.028","article-title":"How to prevent varices from bleeding: shades of grey\u2014the case for nonselective beta blockers","volume":"133","author":"Thalheimer","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2017.01.015_bib0325","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1440-1746.2005.03982.x","article-title":"Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?","volume":"21","author":"Cholongitas","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2017.01.015_bib0335","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non-selective \u03b2-blockers are associated with improved survival in patients with ascites listed for liver transplantation","volume":"64","author":"Leithead","year":"2015","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0340","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Nonselective \u03b2-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients","volume":"63","author":"Bossen","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0345","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2017.01.015_bib0350","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","article-title":"The Epidemiology of Cirrhosis in the United States: A Population-based Study","volume":"49","author":"Scaglione","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2017.01.015_bib0355","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0360","first-page":"A74","article-title":"National trends and disparities in the incidence of hepatocellular carcinoma 1998\u20132003","volume":"5","author":"Ahmed","year":"2008","journal-title":"Prev. Chronic Dis."},{"issue":"5 Suppl. 1","key":"10.1016\/j.phrs.2017.01.015_bib0365","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.phrs.2017.01.015_bib0370","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jhep.2005.11.009","article-title":"Natural history and predictors of disease severity in chronic hepatitis C","volume":"44","author":"Massard","year":"2006","journal-title":"J. Hepatol."},{"issue":"9055","key":"10.1016\/j.phrs.2017.01.015_bib0375","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0380","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1989.136","article-title":"Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects","volume":"46","author":"Walle","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0385","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)11136-1","article-title":"Age and gender influence the stereoselective pharmacokinetics of propranolol","volume":"261","author":"Gilmore","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0390","first-page":"185","article-title":"Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans","volume":"4","author":"Mehvar","year":"2001","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2017.01.015_bib0395","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0090-9556(25)08435-1","article-title":"Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase","volume":"22","author":"Masubuchi","year":"1994","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0400","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/bit.20744","article-title":"Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450","volume":"93","author":"Otey","year":"2006","journal-title":"Biotechnol. Bioeng."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","article-title":"Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers","volume":"51","author":"H\u00e4gg","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2017.01.015_bib0410","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF03190261","article-title":"Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype","volume":"21","author":"Llerena","year":"1996","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.phrs.2017.01.015_bib0415","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002280050615","article-title":"CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences","volume":"55","author":"Tamminga","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2017.01.015_bib0420","first-page":"1265","article-title":"Assessment of sex differences in Pharmacokinetics of carvedilol in human","volume":"27","author":"Abbas","year":"2014","journal-title":"Pak. J. Pharm. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816307903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816307903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:32:38Z","timestamp":1749907958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816307903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":84,"alternative-id":["S1043661816307903"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.01.015","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}